Browsing by author "Sottoriva, Andrea"
Now showing items 1-20 of 53
-
A Big Bang model of human colorectal tumor growth.
Sottoriva, A; Kang, H; Ma, Z; Graham, TA; Salomon, MP; et al. (NATURE PUBLISHING GROUP, 2015-03-01)What happens in early, still undetectable human malignancies is unknown because direct observations are impractical. Here we present and validate a 'Big Bang' model, whereby tumors grow predominantly as a single expansion ... -
Analysis of tumour ecological balance reveals resource-dependent adaptive strategies of ovarian cancer.
Nawaz, S; Trahearn, NA; Heindl, A; Banerjee, S; Maley, CC; et al. (ELSEVIER, 2019-10-21)BACKGROUND: Despite treatment advances, there remains a significant risk of recurrence in ovarian cancer, at which stage it is usually incurable. Consequently, there is a clear need for improved patient stratification. ... -
Between-region genetic divergence reflects the mode and tempo of tumor evolution.
Sun, R; Hu, Z; Sottoriva, A; Graham, TA; Harpak, A; et al. (NATURE PUBLISHING GROUP, 2017-06-05)Given the implications of tumor dynamics for precision medicine, there is a need to systematically characterize the mode of evolution across diverse solid tumor types. In particular, methods to infer the role of natural ... -
Cancer Evolution: A Multifaceted Affair.
Ciriello, G; Magnani, L; Aitken, SJ; Akkari, L; Behjati, S; et al. (American Association for Cancer Research (AACR), 2024-01-12)UNLABELLED: Cancer cells adapt and survive through the acquisition and selection of molecular modifications. This process defines cancer evolution. Building on a theoretical framework based on heritable genetic changes has ... -
Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer.
Lote, H; Spiteri, I; Ermini, L; Vatsiou, A; Roy, A; et al. (2017-06)Background Patients often ask oncologists how long a cancer has been present before causing symptoms or spreading to other organs. The evolutionary trajectory of cancers can be defined using phylogenetic approaches but ... -
Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer.
Lote, H; Spiteri, I; Ermini, L; Vatsiou, A; Roy, A; et al. (OXFORD UNIV PRESS, 2017-02-23)BACKGROUND: Patients often ask oncologists how long a cancer has been present before causing symptoms or spreading to other organs. The evolutionary trajectory of cancers can be defined using phylogenetic approaches but ... -
Catch my drift? Making sense of genomic intra-tumour heterogeneity.
Sottoriva, A; Barnes, CP; Graham, TA (ELSEVIER, 2017-04-01)The cancer genome is shaped by three components of the evolutionary process: mutation, selection and drift. While many studies have focused on the first two components, the role of drift in cancer evolution has received ... -
Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours.
Stankunaite, R; George, SL; Gallagher, L; Jamal, S; Shaikh, R; et al. (ELSEVIER SCI LTD, 2021-12-18)OBJECTIVE: Clinical diagnostic sequencing of circulating tumour DNA (ctDNA) is well advanced for adult patients, but application to paediatric cancer patients lags behind. METHODS: To address this, we have developed a ... -
Classifying the evolutionary and ecological features of neoplasms.
Maley, CC; Aktipis, A; Graham, TA; Sottoriva, A; Boddy, AM; et al. (NATURE PUBLISHING GROUP, 2017-10-01)Neoplasms change over time through a process of cell-level evolution, driven by genetic and epigenetic alterations. However, the ecology of the microenvironment of a neoplastic cell determines which changes provide adaptive ... -
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype.
Lupo, B; Sassi, F; Pinnelli, M; Galimi, F; Zanella, ER; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2020-08-05)Blockade of epidermal growth factor receptor (EGFR) causes tumor regression in some patients with metastatic colorectal cancer (mCRC). However, residual disease reservoirs typically remain even after maximal response to ... -
Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone.
Piccirillo, SG; Spiteri, I; Sottoriva, A; Touloumis, A; Ber, S; et al. (AMER ASSOC CANCER RESEARCH, 2015-01-01)Glioblastoma, the most common and aggressive adult brain tumor, is characterized by extreme phenotypic diversity and treatment failure. Through fluorescence-guided resection, we identified fluorescent tissue in the ... -
Detecting repeated cancer evolution from multi-region tumor sequencing data.
Caravagna, G; Giarratano, Y; Ramazzotti, D; Tomlinson, I; Graham, TA; et al. (NATURE PUBLISHING GROUP, 2018-08-31)Recurrent successions of genomic changes, both within and between patients, reflect repeated evolutionary processes that are valuable for the anticipation of cancer progression. Multi-region sequencing allows the temporal ... -
Detecting truly clonal alterations from multi-region profiling of tumours.
Werner, B; Traulsen, A; Sottoriva, A; Dingli, D (NATURE PORTFOLIO, 2017-03-27)Modern cancer therapies aim at targeting tumour-specific alterations, such as mutations or neo-antigens, and maximal treatment efficacy requires that targeted alterations are present in all tumour cells. Currently, treatment ... -
Divergent adaptation in thyroid cancers.
Sottoriva, A (OXFORD UNIV PRESS, 2018-06-01) -
EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.
Smyth, EC; Vlachogiannis, G; Hedayat, S; Harbery, A; Hulkki-Wilson, S; et al. (BMJ PUBLISHING GROUP, 2020-11-16)OBJECTIVE: Epidermal growth factor receptor (EGFR) inhibition may be effective in biomarker-selected populations of advanced gastro-oesophageal adenocarcinoma (aGEA) patients. Here, we tested the association between outcome ... -
Evolutionary dynamics of neoantigens in growing tumors.
Lakatos, E; Williams, MJ; Schenck, RO; Cross, WCH; Househam, J; et al. (NATURE PORTFOLIO, 2020-10-01)Cancers accumulate mutations that lead to neoantigens, novel peptides that elicit an immune response, and consequently undergo evolutionary selection. Here we establish how negative selection shapes the clonality of ... -
Evolutionary dynamics of residual disease in human glioblastoma.
Spiteri, I; Caravagna, G; Cresswell, GD; Vatsiou, A; Nichol, D; et al. (OXFORD UNIV PRESS, 2019-03-01)BACKGROUND: Glioblastoma is the most common and aggressive adult brain malignancy against which conventional surgery and chemoradiation provide limited benefit. Even when a good treatment response is obtained, recurrence ... -
Exploiting evolutionary steering to induce collateral drug sensitivity in cancer.
Acar, A; Nichol, D; Fernandez-Mateos, J; Cresswell, GD; Barozzi, I; et al. (NATURE PORTFOLIO, 2020-04-21)Drug resistance mediated by clonal evolution is arguably the biggest problem in cancer therapy today. However, evolving resistance to one drug may come at a cost of decreased fecundity or increased sensitivity to another ... -
Functional versus non-functional intratumor heterogeneity in cancer.
Williams, MJ; Werner, B; Graham, TA; Sottoriva, A (2016-07)Next-generation sequencing data from human cancers are often difficult to interpret within the context of tumor evolution. We developed a mathematical model describing the accumulation of mutations under neutral evolutionary ... -
Germline MBD4 deficiency causes a multi-tumor predisposition syndrome.
Palles, C; West, HD; Chew, E; Galavotti, S; Flensburg, C; et al. (CELL PRESS, 2022-05-05)We report an autosomal recessive, multi-organ tumor predisposition syndrome, caused by bi-allelic loss-of-function germline variants in the base excision repair (BER) gene MBD4. We identified five individuals with bi-allelic ...